The NEXT Project: Network Enriched Crossover Trials

About The NEXT Project: Network Enriched Crossover Trials
  • Precision medicine involves the prescription of treatments based on the unique biology of an individual’s tumor. Understanding how various molecular alterations integrate to promote tumor biology will inform better selection of appropriate medications for an individual patient.
  • Dr. Ryan and team will evaluate alterations in the genomes of tumors from castrate-resistant prostate cancer (CRPC) patients enrolled in ongoing clinical trials to define biomarkers that predict treatment responses and resistance. These biomarkers will be used to guide enrollment of patients into subsequent clinical trials and will signal the need for a different treatment strategy.
  • Biomarkers will be developed to predict: (1) development of resistance to second-generation AR-targeting drugs (enzalutamide or abiraterone); (2) which patients will benefit from cross-over to another agent; (3) responsiveness to non-AR pathway-targeting drugs; and (4) sensitivity to chemotherapy.

What this means for patients: Precision medicine is the future of clinical practice. Genomic analysis of an individual’s tumor will be used to select the optimal treatment during the continuum of clinical progression of prostate cancer. If successful, this project will define and validate genomic biomarkers that predict tumor responses to various drugs and will guide more effective therapy throughout the course of an individual’s disease.

Principal Investigator:

Charles Ryan, MD (University of California, San Francisco)

Co-investigators:

Eric Small, MD (University of California, San Francisco), Josh Stuart, PhD (University of California, Santa Cruz), Pamela Paris, PhD (University of California, San Francisco), Jack Youngren, PhD (University of California, San Francisco), Won Kim, MD, (University of California, San Francisco), Rahul Aggarwal, MD (University of California, San Francisco), Li Zhang, PhD (University of California, San Francisco), Ted Goldstein, PhD (University of California, Santa Cruz), Robert Baertsch, PhD (University of California, Santa Cruz).